Retatrutide and Bodybuilding: Body Composition Data

The Short Answer

Retatrutide has generated significant interest in the bodybuilding and fitness community due to its triple receptor profile (GIP/GLP-1/glucagon), the largest mean weight reductions reported in any late-stage obesity trial, and the theoretical metabolic advantages conferred by glucagon receptor agonism. Phase 2 DXA body composition data, published by Coskun and colleagues in The Lancet Diabetes & Endocrinology (2025), provide the most detailed look at how retatrutide affects fat mass, lean mass, and regional fat distribution.

The data show substantial fat loss with a lean mass preservation profile roughly comparable to other incretin-based obesity therapies. However, retatrutide is an investigational drug — not approved, not available in clinical-grade form, and associated with significant adverse events including a dysesthesia signal affecting up to 20.9% of participants at the highest dose.

This article presents the clinical evidence. It does not endorse off-label use of any investigational compound.

Why Bodybuilders Are Interested

The bodybuilding community’s interest in retatrutide centers on several pharmacological properties that distinguish it from other incretin-based therapies:

1. Triple receptor agonism. Retatrutide activates GIP, GLP-1, and glucagon receptors. The glucagon component is unique among obesity drugs in clinical development and has theoretical implications for thermogenesis and fat oxidation.
2. Record weight loss. TRIUMPH-4 demonstrated -28.7% mean body weight loss at 12 mg over 68 weeks — the largest reduction in any Phase 3 obesity trial. For bodybuilders seeking aggressive fat loss during cutting phases, this magnitude of effect is noteworthy.
3. Glucagon-driven thermogenesis. Glucagon receptor activation increases resting energy expenditure and promotes brown adipose tissue thermogenesis in animal models. This has led to speculation that retatrutide might offer a metabolic advantage over GLP-1-only or GIP/GLP-1 dual agonists for fat loss.
4. Visceral fat targeting. The Phase 2 DXA data showed particularly large reductions in android (visceral) fat, which is of interest to physique athletes seeking visible abdominal definition.

These pharmacological features have made retatrutide a topic of widespread discussion in bodybuilding forums, YouTube channels, and fitness media. However, the clinical data tell a more nuanced story than the enthusiasm might suggest.

Body Composition Data: Coskun 2025 (Lancet D&E)

The most informative dataset on retatrutide’s effects on body composition comes from a DXA substudy within the Phase 2 trial, published by Coskun and colleagues in The Lancet Diabetes & Endocrinology in 2025.

Study Parameters

• Enrolled: 189 participants in the DXA substudy
• Completed DXA scans at 36 weeks: 103 participants
• Completion rate: approximately 55% — a significant limitation when interpreting results
• Population: This substudy was conducted in participants with type 2 diabetes, not the general obesity population. Body composition responses may differ between populations.
• Duration: 36 weeks (shorter than the 48-week Phase 2 primary endpoint and the 68-week Phase 3 duration)
• Doses evaluated: 0.5 mg, 4 mg, 8 mg, and 12 mg (Phase 2 doses; the Phase 3 program uses 9 mg and 12 mg with an updated escalation protocol including a 6 mg step)

Fat Mass Reduction

The apparent plateau or slight decrease from 8 mg to 12 mg in fat mass reduction should be interpreted cautiously given the small sample sizes at each dose and the 45% dropout rate in the DXA substudy.

Fat-to-Lean Mass Loss Ratio

At the 12 mg dose, the composition of weight lost was approximately:

• 74% fat mass
• 26% lean mass

This ratio is a critical metric for the bodybuilding community. Total weight loss is less informative than the composition of that loss — a drug that produces 30% weight loss but strips 50% lean mass is fundamentally different from one that preserves muscle.

How Does Retatrutide Compare?

Retatrutide’s lean mass preservation appears comparable to or slightly better than semaglutide and roughly similar to tirzepatide. However, direct head-to-head comparisons have not been conducted, and differences in study populations, durations, and measurement methods make cross-trial comparisons imprecise.

Absolute Lean Mass Loss

The preservation ratio should not obscure the absolute numbers. At the highest Phase 2 doses, participants lost up to 6.5 kg of lean mass over 36 weeks. For a 100 kg individual, this represents approximately 6.5% of total body weight lost as lean tissue.

For bodybuilders who have spent years building muscle mass, a potential loss of 6-7 kg of lean tissue is a significant concern. Whether resistance training and high protein intake can mitigate this loss in a retatrutide-treated population has not been studied.

Android (Visceral) Fat Reduction

The DXA data showed particularly large reductions in android fat — the visceral and subcutaneous fat in the abdominal region:

• Android fat reduction at 12 mg: -31.4%
• This was proportionally greater than total body fat reduction, suggesting preferential visceral fat mobilization

Visceral fat reduction is relevant to both metabolic health and physique aesthetics. The android fat compartment overlays the abdominal musculature and its reduction directly improves visible muscle definition in that region.

The Glucagon Receptor Question

The glucagon receptor component is what most distinguishes retatrutide from semaglutide and tirzepatide in the context of body composition. Glucagon receptor activation produces several effects relevant to fat loss:

Animal Data

• Increased resting energy expenditure (REE): Glucagon stimulates hepatic thermogenesis and increases metabolic rate in rodent models
• Brown adipose tissue activation: Glucagon promotes brown fat thermogenesis, converting stored energy to heat rather than storing it
• Increased fat oxidation: Glucagon shifts substrate utilization toward fatty acid oxidation
• Hepatic lipid mobilization: Glucagon promotes the release of stored triglycerides from the liver

Human Relevance: Uncertain

The clinical significance of glucagon receptor agonism for body composition in humans remains uncertain:

• Human brown adipose tissue volume is much smaller than in rodents, and its contribution to total energy expenditure is debated
• Phase 2 indirect calorimetry data for retatrutide have not been published
• The resting energy expenditure increase attributable specifically to the glucagon component versus the GLP-1 and GIP components has not been isolated in human studies
• The liver fat reduction seen with retatrutide (82% at 12 mg in Phase 2a) may reflect glucagon-driven hepatic lipid mobilization, but this does not directly translate to improved subcutaneous fat loss

The bodybuilding community’s enthusiasm about glucagon-mediated thermogenesis is based primarily on animal data and theoretical pharmacology. Whether this translates to a meaningful fat-loss advantage in humans — beyond what GLP-1 agonism alone provides — is unproven.

Clinical Trial Context: What Participants Actually Did

The Phase 2 trial in which the body composition data were collected included baseline lifestyle interventions:

• Caloric deficit: 500 kcal/day reduction from estimated maintenance
• Physical activity: 150 minutes per week of moderate-intensity exercise

These are modest interventions by bodybuilding standards. The study population consisted of adults with obesity (mean BMI ~37), not trained athletes. No resistance training protocol was specified, and protein intake was not standardized beyond general dietary guidance.

This context matters: the body composition outcomes reflect retatrutide’s effects in a sedentary-to-moderately-active obese population consuming a standard deficit diet. Outcomes in resistance-trained individuals consuming high-protein diets and performing structured hypertrophy or strength training may differ substantially — but this population has not been studied.

Protein and Training Recommendations from the Literature

While no retatrutide-specific guidelines exist for optimizing body composition, the broader obesity pharmacotherapy literature and exercise science research suggest:

Protein Intake

• 1.2-2.0 g/kg/day of protein is recommended during caloric restriction to attenuate lean mass loss
• The higher end of this range (1.6-2.0 g/kg/day) may be particularly important during aggressive weight loss, which retatrutide certainly produces
• GLP-1 agonists reduce appetite significantly, which can make achieving high protein intakes challenging — deliberate protein prioritization in meal planning is essential
• Protein timing (distribution across 3-4 meals with 30-40g per feeding) may further support muscle protein synthesis

Resistance Training

• 2-5 sessions per week of resistance training is the most effective intervention for preserving lean mass during caloric restriction
• Progressive overload principles should be maintained even during weight loss phases
• Compound movements that recruit large muscle groups are prioritized
• Training volume may need to be managed carefully given the GI side effects common with GLP-1 agonists (nausea, vomiting, diarrhea) — training timing relative to meals and injection timing may require adjustment

What Has Not Been Studied

No clinical trial has evaluated retatrutide in combination with:

• Structured resistance training programs
• High-protein diets (>1.5 g/kg/day)
• Other body composition optimization strategies common in the bodybuilding community
• Anabolic androgenic steroids or other performance-enhancing compounds

The absence of this data means that any claims about retatrutide’s effects in a trained, protein-optimized population are extrapolations, not evidence.

Critical Warnings

Retatrutide Is Not Approved

Retatrutide has no FDA approval, no EMA approval, and no regulatory marketing authorization anywhere in the world as of March 2026. There is no pharmaceutical-grade product available for purchase. Any product sold online as “retatrutide” is not manufactured under GMP conditions and lacks quality verification for identity, purity, potency, and sterility.

Gray Market Peptide Risks

Products marketed as retatrutide through research peptide vendors carry inherent risks:

• Unknown identity and purity: Independent testing of gray-market peptides has repeatedly found discrepancies between label claims and actual content
• No sterility assurance: Injectable products require validated sterility processes that unregulated vendors cannot guarantee
• No dose accuracy: Without validated potency testing, the actual amount of peptide per vial is unknown, making accurate dosing impossible
• No batch traceability: Quality issues cannot be tracked or recalled

Dysesthesia Is Not a Minor Side Effect

The dysesthesia signal observed in TRIUMPH-4 deserves particular emphasis in the bodybuilding context, where side effects are sometimes minimized:

• 20.9% incidence at 12 mg (vs. 0.7% placebo)
• 8.8% incidence at 9 mg
• Characterized as tingling, numbness, or burning sensations — primarily in extremities
• The mechanism is not fully understood
• For individuals who rely on neuromuscular control and proprioception during heavy resistance training, sensory nerve disturbances are not trivial

Discontinuation Rates

• 18.2% of participants at 12 mg discontinued treatment due to adverse events in TRIUMPH-4
• This rate reflects a medically supervised population with structured dose escalation — rates in unsupervised self-administration may be higher

No Data on Compound Interactions

Many bodybuilders use multiple pharmacological agents simultaneously. There are zero data on interactions between retatrutide and:

• Anabolic androgenic steroids (testosterone, nandrolone, trenbolone, etc.)
• Selective androgen receptor modulators (SARMs)
• Growth hormone or growth hormone secretagogues
• Insulin or insulin sensitizers
• Thyroid hormones (T3, T4)
• Stimulants or thermogenics (clenbuterol, ephedrine, caffeine)
• Diuretics

Combining an investigational triple receptor agonist with other compounds in the absence of any interaction data represents uncharacterized risk.

Frequently Asked Questions

Is retatrutide better than semaglutide for cutting?

Retatrutide produces greater total weight loss than semaglutide (28.7% vs. ~15% at Phase 3 doses), and its lean mass preservation ratio (~26% lean loss) appears more favorable than semaglutide (approximately 35-40% lean loss in the STEP-1 trial; Wilding et al., NEJM 2021). However, these comparisons are across different trials with different populations and durations. No head-to-head study has compared these agents in a body composition context, and neither has been studied in resistance-trained individuals.

Does retatrutide preserve muscle better than other GLP-1 drugs?

Phase 2 DXA data suggest retatrutide’s fat-to-lean loss ratio (~74:26) is comparable to tirzepatide and better than semaglutide. However, absolute lean mass loss was still up to 6.5 kg at higher doses over 36 weeks. Whether resistance training and high protein intake can improve this ratio in retatrutide-treated individuals has not been studied.

Does the glucagon component give retatrutide an edge for fat loss?

In theory, glucagon receptor activation increases resting energy expenditure and promotes fat oxidation. In animal models, these effects are well-documented. In humans, the clinical significance of this mechanism is uncertain. No published data isolate the contribution of the glucagon component to retatrutide’s fat loss versus the GLP-1 and GIP components.

Does retatrutide have any role during weight gain or muscle-building phases?

There is no clinical rationale for using a potent appetite suppressant and weight loss agent during a caloric surplus phase intended for muscle accretion. Retatrutide dramatically reduces appetite and food intake — effects that are fundamentally incompatible with the caloric requirements of a weight gain phase. Additionally, the gastrointestinal side effects (nausea in 43.2%, vomiting in 20.9% at 12 mg) would impair the ability to consume the volume of food required for lean mass gain. No clinical data exist on retatrutide use during intentional weight gain phases.

What dose would bodybuilders use?

This question presupposes access to a pharmaceutical-grade product, which does not exist outside of clinical trials. The Phase 3 dose escalation protocol is 2 mg → 4 mg → 6 mg → 9 mg → 12 mg with 4-week intervals between steps. The Phase 2 body composition data were collected at doses up to 12 mg. No dose optimization for body composition (as opposed to total weight loss) has been studied.

Is it safe to combine retatrutide with anabolic steroids?

There are zero data on this combination. No clinical trial has evaluated retatrutide in individuals using anabolic androgenic steroids or any other performance-enhancing drugs. The metabolic, hepatic, cardiovascular, and neurological effects of combining a triple receptor agonist with anabolic compounds are entirely uncharacterized. This represents unknown risk.

Summary

Retatrutide’s Phase 2 DXA data show substantial fat loss (up to 26.1% fat mass reduction at 36 weeks), preferential visceral fat mobilization (-31.4% android fat at 12 mg), and a lean mass preservation ratio (~74% fat / 26% lean) that is comparable to or slightly better than other incretin-based therapies. The glucagon receptor component has theoretical advantages for thermogenesis and fat oxidation, but the human clinical significance of these effects is unproven. Absolute lean mass loss of up to 6.5 kg remains a concern, and no data exist on retatrutide in resistance-trained, protein-optimized populations. Retatrutide is investigational, not approved, and not available in clinical-grade form. The dysesthesia signal (20.9% at 12 mg) and high GI adverse event rates represent meaningful safety concerns that should not be minimized. No data exist on interactions with anabolic steroids or other compounds commonly used in the bodybuilding community.